Astellas Global Health Foundation and AMPATH Announce a Three-Year $1.35 Million Grant to Aid Mental Health Programming in Western Kenya

On February 10, 2020 The Astellas Global Health Foundation ("Foundation") and the Academic Model Providing Access to Healthcare (AMPATH), under the direction of the Indiana University Center for Global Health, reported that the Foundation has awarded a $1.35 million grant over three years to AMPATH to provide 400,000 people with access to mental health programming in western Kenya (Press release, Astellas, FEB 10, 2020, View Source [SID1234554080]). AMPATH will integrate mental health services into AMPATH’s chronic disease system in public health facilities and broaden population engagement through a mental health awareness campaign. Additionally, AMPATH will provide group transitional housing and care for patients with severe mental health disorders.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The Astellas Global Health Foundation funding will help AMPATH to meaningfully expand our mental health programming, as we are committed to improving access to and quality of mental health care, reducing treatment gaps and empowering patients in western Kenya," said Edith Kwobah, MBChB, MMED, consultant psychiatrist and head of mental health at Moi Teaching and Referral Hospital in Kenya and the Kenyan medical leader of the initiative.

ampath

ampath
"This grant will provide training for community health volunteers to screen for mental health disorders and refer members of the Kenyan community to appropriate care facilities to improve health outcomes for these patients," added Matthew Turissini, M.D., assistant professor of clinical medicine, Indiana University School of Medicine.

Indiana University, which leads the consortium of North American academic health centers within the AMPATH partnership, will serve as the administrator for the grant.

According to the World Health Organization, 75 percent of people affected by mental health disorders in low-income countries do not have access to the treatment they need.1 This is partially due to funding in many of these countries being prioritized to address infectious diseases2 and the significant stigma of mental illness.3 The grant from the Astellas Global Health Foundation will help AMPATH address this treatment gap in western Kenya.

"Access to mental health care is a worldwide issue with a particularly significant lack of proper diagnosis and treatment among low- and middle-income populations," said Moyra Knight, president of the Astellas Global Health Foundation. "The important work AMPATH is doing in western Kenya improves the diagnosis and sustains treatment of mental illness for communities in critical need."

For the Astellas Global Health Foundation, formed in November 2018, this investment is the first focused on mental health, which is one of the Foundation’s key focus areas in improving access to health in low- and middle-income countries where Astellas, a company dedicated to improving the health of people around the world, does not have a business presence. Additional priorities for Foundation funding are creating community resilience and providing grants for disaster support.

Corporate Presentation, dated February 2020

On February 10, 2020 Tracon Pharmaceuticals Presented the Corporate Presentation (Presentation, Tracon Pharmaceuticals, FEB 10, 2020, View Source [SID1234554078]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!


MacroGenics to Participate in Upcoming Investor Conferences

On February 10, 2020 MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, reported that the Company’s management will attend the following investor conferences in February (Press release, MacroGenics, FEB 10, 2020, View Source [SID1234554077]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Guggenheim Healthcare Talks 2nd Annual Oncology Day. MacroGenics’ management will participate in a fireside chat with the analyst in New York City on Thursday, February 13, 2020, at 4:00 p.m. ET.
SVB Leerink 9th Annual Global Healthcare Conference. MacroGenics’ management will participate in a fireside chat with the analyst in New York City on Wednesday, February 26, 2020, at 10:00 a.m. ET.
Webcasts of the fireside chats may be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics’ website at View Source The Company will maintain archived replays of these webcasts on its website for 30 days after the conference.

Chi-Med Highlights Updated Phase II Savolitinib / Imfinzi® Combination Data in Advanced Papillary Renal Cell Carcinoma at 2020 ASCO Genitourinary Cancers Symposium

On February 10, 2020 Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) reported the availability of updated results from the Phase II CALYPSO study of the savolitinib / Imfinzi (durvalumab) combination in a cohort of patients with metastatic papillary renal cell carcinoma ("PRCC"), an investigator initiated study led by Professor Thomas Powles, Lead for Solid Tumour Research at Barts Cancer Centre, and sponsored by Queen Mary University of London (Press release, Hutchison China MediTech, FEB 10, 2020, View Source [SID1234554076]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Full data from the PRCC cohort of the CALYPSO study will be presented on Saturday, February 15, 2020, in oral and poster presentations at the annual American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Genitourinary Cancers Symposium ("ASCO GU") in San Francisco, CA.

Further details from the presentation are as follows:

Presentation Title:

Overall survival results for durvalumab and savolitinib in metastatic papillary renal cancer

Presenting Author:

Cristina Suarez Rodriguez, Vall d’Hebron University Hospital and Institute of Oncology, Barcelona, Spain

Other Authors:

Thomas Powles, James M. G. Larkin, Poulam Patel, Begoña Pérez-Valderrama, Alejo Rodriguez-Vida, Hilary Glen, Fiona Thistlethwaite, Christy Ralph, Srinivasan Gopalakrishnan, Maria Jose Mendez-Vidal, Kelly Mousa, Aaron Prendergast, Laura Vosper, Wing-Kin Liu

Abstract #:

619 / Board D5

Oral Presentation:

Rapid Abstract Session C: Renal Cell Cancer

Date & Time:

Saturday, February 15: 11:35 AM-12:30 PM PST

Poster Presentation:

Session C: Renal Cell Cancer

Date & Time:

Saturday, February 15: 7:00 AM-7:55 AM PST

Preliminary results of this study (cut-off date of September 25, 2018) were first presented on February 16, 2019 at ASCO (Free ASCO Whitepaper)-GU.1

1 Powles,et al. A phase II study investigating the safety and efficacy of savolitinib and durvalumab in metastatic papillary renal cancer (CALYPSO). 2019 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Genitourinary Cancers Symposium Abstract #545. Presented on February 16, 2019.

About PRCC in the CALYPSO study

PRCC is a subtype of kidney cancer that is unusually difficult to treat, with low response rates from current treatment options and no treatments approved for this specific indication. The CALYPSO study is an independently sponsored open-label Phase II study of Imfinzi in combination with several drug candidates in the treatment of renal cell carcinoma in the U.K. and Spain. Several arms of CALYPSO are evaluating the treatment of PRCC and clear cell renal carcinoma (ccRCC) with savolitinib, a highly selective inhibitor of the MET receptor tyrosine kinase, both as a monotherapy and in combination with Imfinzi (durvalumab), AstraZeneca’s anti-programmed death-ligand 1 (PD-L1) antibody. CALYPSO enrolls an all-comer PRCC population with planned retrospective molecular profiling. For further details, please refer to clinicaltrials.gov number NCT02819596.

About Savolitinib

Savolitinib is a potential first-in-class inhibitor of MET, an enzyme which has been shown to function abnormally in many types of solid tumors. Chi-Med designed savolitinib to be a potent and highly selective oral inhibitor, which, through chemical structure modification, addresses human metabolite-related renal toxicity, the primary issue that halted development of several other selective MET inhibitors. In clinical studies to date, involving over 1,000 patients, savolitinib has shown promising signs of clinical efficacy in patients with MET gene alterations in multiple tumor types with an acceptable safety profile. Chi-Med is currently testing savolitinib in global partnership with AstraZeneca, both as a monotherapy and in combination with immunotherapy, targeted therapy and chemotherapy drugs.

Aclaris Therapeutics to Present at the SVB Leerink 9th Annual Global Healthcare Conference

On February 10, 2020 Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, reported that management will present a company overview at the SVB Leerink 9th Annual Global Healthcare Conference on Thursday, February 27, 2020 at 10:00 AM ET in New York, New York (Press release, Aclaris Therapeutics, FEB 10, 2020, View Source [SID1234554075]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of the presentation may be accessed through the Company’s web site, www.aclaristx.com, on the ‘Events’ section. An archived version of the presentation will be available for 30 days.